Cost of multiple sclerosis in the Czech Republic: The COMS study

Multiple Sclerosis Journal

Volumn 18, Issue 5, 2012, Pages 662-668

  Blahova Dusankova, J ^a   Kalincik, T ^a   Dolezal, T ^b,c   Kobelt, G ^d   Havrdova, E ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

^b Institute of Health Economics and Technology Assessment   (Czech Republic)

^c CHARLES UNIVERSITY   (Czech Republic)

^d LUND UNIVERSITY   (Sweden)

Author keywords

cost of illness; Czech Republic; direct costs; disability; indirect costs; multiple sclerosis

Indexed keywords

DISEASE MODIFYING DRUG; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CZECH REPUBLIC; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG USE; EXPANDED DISABILITY STATUS SCALE; FEMALE; HEALTH CARE COST; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; RELAPSE; SOCIAL CARE;

EID: 84860443369     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458511424422     Document Type: Article

References (18)

1. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology. 1993 ; 43: 662-667
2. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet. 1998 ; 352: 1498-1504
3. Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol. 1996 ; 39: 285-294
4. Kobelt G, Berg J, Lindgren P, Fredrikson S, Jonsson B. Costs and quality of life of patients with multiple sclerosis in Europe. J Neurol Neurosurg Psychiatry. 2006 ; 77: 918-926
5. Orlewska E, Mierzejewski P, Zaborski J, Kruszewska J, Wicha W, Fryze W, et al. A prospective study of the financial costs of multiple sclerosis at different stages of the disease. Eur J Neurol. 2005 ; 12: 31-39
6. Ann Neurol. Polman CH Reingold SC Edan G Filippi M Hartung HP Kappos L, ed. 2005: 840-846.
7. Kobelt G, Berg J, Lindgren P, Anten B, Ekman M, Jongen PJ, et al. Costs and quality of life in multiple sclerosis in The Netherlands. Eur J Health Econ. 2006 ; 7: S55 - S64
8. Kobelt G, Berg J, Atherly D, Hadjimichael O. Costs and quality of life in multiple sclerosis: a cross-sectional study in the United States. Neurology. 2006 ; 66: 1696-1702
9. Kobelt G, Berg J, Lindgren P, Kerrigan J, Russell N, Nixon R. Costs and quality of life of multiple sclerosis in the United Kingdom. Eur J Health Econ. 2006 ; 7: S96 - S104
10. Kobelt G, Berg J, Lindgren P, Elias WG, Flachenecker P, Freidel M, et al. Costs and quality of life of multiple sclerosis in Germany. Eur J Health Econ. 2006 ; 7: S34 - S44
11. Taylor B, McDonald E, Fantino B, Sedal L, MacDonnell R, Pittas F, et al. The cost of multiple sclerosis in Australia. J Clin Neurosci. 2007 ; 14: 532-539
12. Kobelt G, Berg J, Lindgren P, Plesnilla C, Baumhackl U, Berger T, et al. Costs and quality of life of multiple sclerosis in Austria. Eur J Health Econ. 2006 ; 7: S14 - S23
13. Kobelt G, Berg J, Lindgren P, Battaglia M, Lucioni C, Uccelli A. Costs and quality of life of multiple sclerosis in Italy. Eur J Health Econ. 2006 ; 7: S45-54
14. Sharac J, McCrone P, Sabes-Figuera R. Pharmacoeconomic considerations in the treatment of multiple sclerosis. Drugs. 2010 ; 70: 1677-1691
15. Pugliatti M, Rosati G, Carton H, Riise T, Drulovic J, Vecsei L, et al. The epidemiology of multiple sclerosis in Europe. Eur J Neurol. 2006 ; 13: 700-722
16. KobeltGKastengF. Access to innovative treatments in multiple sclerosis in Europe, 2009 [06/05/2011]. Available from: http://www.comparatorreports.se/ Access%20to%20MS%20treatments%20-%20October%202009.pdf.
17. Naci H, Fleurence R, Birt J, Duhig A. The impact of increasing neurological disability of multiple sclerosis on health utilities: a systematic review of the literature. J Med Econ. 2010 ; 13: 78-89
18. Phillips CJ. The cost of multiple sclerosis and the cost effectiveness of disease-modifying agents in its treatment. CNS Drugs. 2004 ; 18: 561-574